DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Trial of PTK787/ZK 222584 Plus Paclitaxel

Phase 1

Terminated

Conditions: Metastatic Non-hematologic Malignancies

Interventions: Drug: PTK787/ZK 222584
Drug: paclitaxel

First Posted Date: 2006-07-31

Last Posted Date: 2022-04-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 7

Registration Number: NCT00358163

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Phase 2

Completed

Conditions: Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific
Lymphoma
Central Nervous System Tumor, Pediatric
Leukemia
Sarcoma

Interventions: Drug: celecoxib
Drug: cyclophosphamide
Drug: etoposide
Drug: fenofibrate
Drug: thalidomide

First Posted Date: 2006-07-27

Last Posted Date: 2014-10-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT00357500

Locations: 🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

and more 7 locations

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

Not Applicable

Completed

Conditions: Hematologic Malignancies

First Posted Date: 2006-07-21

Last Posted Date: 2009-03-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT00355407

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation

Not Applicable

Completed

Conditions: Hematologic Malignancy
AML
ALL
CML
Multiple Myeloma
NHL
Hodgkin's Lymphoma

First Posted Date: 2006-06-02

Last Posted Date: 2012-03-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00333190

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Rituximab
Drug: Alemtuzumab

First Posted Date: 2006-05-26

Last Posted Date: 2016-05-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00330252

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

Phase 2

Terminated

Conditions: Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Ovarian Cancer
Mixed Tumor, Mesodermal

Interventions: Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-05-08

Last Posted Date: 2018-09-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00322881

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: Autologous, Lethally Irradiated Breast Cancer Cells

First Posted Date: 2006-04-25

Last Posted Date: 2022-04-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00317603

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2006-03-10

Last Posted Date: 2020-10-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT00301093

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation

Phase 2

Completed

Conditions: Graft Versus Host Disease
GVHD

First Posted Date: 2006-01-26

Last Posted Date: 2014-05-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT00282282

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer

Phase 2

Conditions: Post-Menopausal
Breast Cancer

First Posted Date: 2006-01-24

Last Posted Date: 2007-01-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00280930

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy